Expression of interleukin-17 is correlated with interferon-α expression in cutaneous lesions of lupus erythematosus

Clinical and Experimental Dermatology

Volumn 36, Issue 5, 2011, Pages 512-520

  Oh, S H ^a   Roh, H J ^a   Kwon, J E ^a   Lee, S H ^a   Kim, J Y ^a   Choi, H J ^b   Lim, B J ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Chungnam National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 6; MYXOVIRUS RESISTANCE PROTEIN A; TRANSFORMING GROWTH FACTOR BETA;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATORY CELL; KERATINOCYTE; LUPUS ERYTHEMATOSUS; MALE; PANNICULITIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN DEFECT;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; CYTOKINES; FEMALE; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-17; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, DISCOID; MALE; MIDDLE AGED; PANNICULITIS, LUPUS ERYTHEMATOSUS; SEVERITY OF ILLNESS INDEX; SKIN; TRANSFORMING GROWTH FACTOR BETA; YOUNG ADULT;

EID: 79959342374     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2010.03996.x     Document Type: Article

References (53)

1. Crowson AN, Magro C. The cutaneous pathology of lupus erythematosus: a review. J Cutan Pathol 2001; 28: 1-23.
2. Wenzel J, Zahn S, Bieber T, Tuting T. Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus. Arch Dermatol Res 2009; 301: 83-6.
3. Weissmann C, Weber H. The interferon genes. Prog Nucleic Acid Res Mol Biol 1986; 33: 251-300.
4. Wenzel J, Tuting T. Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches. Exp Dermatol 2007; 16: 454-63.
5. Dall'era MC, Cardarelli PM, Preston BT et al. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005; 64: 1692-7.
6. Arrue I, Saiz A, Ortiz-Romero PL, Rodriguez-Peralto JL. Lupus-like reaction to interferon at the injection site. report of five cases. J Cutan Pathol 2007; 34 (Suppl. 1): 18-21.
7. Fah J, Pavlovic J, Burg G. Expression of MxA protein in inflammatory dermatoses. J Histochem Cytochem 1995; 43: 47-52.
8. Blomberg S, Eloranta ML, Cederblad B et al. Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 2001; 10: 484-90.
9. Farkas L, Beiske K, Lund-Johansen F et al. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001; 159: 237-43.
10. Meller S, Winterberg F, Gilliet M et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 2005; 52: 1504-16.
11. Wenzel J, Zahn S, Mikus S et al. The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. Br J Dermatol 2007; 157: 752-7.
12. Wenzel J, Worenkamper E, Freutel S et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol 2005; 205: 435-42.
13. Garrett-Sinha LA, John S, Gaffen SL. IL-17 and the Th17 lineage in systemic lupus erythematosus. Curr Opin Rheumatol 2008; 20: 519-25.
14. Bonilla-Martinez ZL, Albrecht J, Troxel AB et al. The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. Arch Dermatol 2008; 144: 173-80.
15. Krathen MS, Dunham J, Gaines E et al. The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatology. Arthritis Rheum 2008; 59: 338-44.
16. Kuhn A, Bijl M. Pathogenesis of cutaneous lupus erythematosus. Lupus 2008; 17: 389-93.
17. Kuhn A, Krammer PH, Kolb-Bachofen V. Pathophysiology of cutaneous lupus erythematosus - novel aspects. Rheumatology 2006; 45 (Suppl. 3): iii14-16.
18. Mohan C, Adams S, Stanik V, Datta SK. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993; 177: 1367-81.
19. Del Prete G. The concept of type-1 and type-2 helper T cells and their cytokines in humans. Int Rev Immunol 1998; 16: 427-55.
20. Lit LC, Wong CK, Li EK, Tam LS, Lam CW, Lo YM. Elevated gene expression of Th1/Th2 associated transcription factors is correlated with disease activity in patients with systemic lupus erythematosus. J Rheumatol 2007; 34: 89-96.
21. Kishimoto T. Interleukin-6: from basic science to medicine - 40years in immunology. Annu Rev Immunol 2005; 23: 1-21.
22. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004; 13: 339-43.
23. Pramanik R, Jorgensen TN, Xin H et al. Interleukin-6 induces expression of Ifi202, an interferon-inducible candidate gene for lupus susceptibility. J Biol Chem 2004; 279: 16121-7.
24. Pestka S, Krause CD, Sarkar D et al. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004; 22: 929-79.
25. Chun HY, Chung JW, Kim HA et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 2007; 27: 461-6.
26. Lit LC, Wong CK, Tam LS et al. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis 2006; 65: 209-15.
27. Tso TK, Huang WN, Huang HY, Chang CK. Elevation of plasma interleukin-18 concentration is associated with insulin levels in patients with systemic lupus erythematosus. Lupus 2006; 15: 207-12.
28. Lauwerys BR, Van SnickJ, Houssiau FA. Serum IL-12 in systemic lupus erythematosus. Absence of p70 heterodimers but presence of p40 monomers correlating with disease activity. Lupus 2002; 11: 384-7.
29. Spadaro A, Scrivo R, Bombardieri M et al. Relationship of interleukin-12 and interleukin-13 imbalance with class-specific rheumatoid factors and anticardiolipin antibodies in systemic lupus erythematosus. Clin Rheumatol 2003; 22: 107-11.
30. Lankford CS, Frucht DM. A unique role for IL-23 in promoting cellular immunity. J Leukoc Biol 2003; 73: 49-56.
31. Aggarwal S, Ghilardi N, Xie MH et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278: 1910-14.
32. Chen Z, Tato CM, Muul L et al. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum 2007; 56: 2936-46.
33. Wong CK, Lit LC, Tam LS et al. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008; 127: 385-93.
34. Kurasawa K, Hirose K, Sano H et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000; 43: 2455-63.
35. Bettelli E, Oukka M, Kuchroo VK. T (H) -17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; 8: 345-50.
36. van Beelen AJ, Teunissen MB, Kapsenberg ML, de Jong EC. Interleukin-17 in inflammatory skin disorders. Curr Opin Allergy Clin Immunol 2007; 7: 374-81.
37. Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007; 148: 32-46.
38. Asarch A, Barak O, Loo DS, Gottlieb AB. Th17 cells: a new therapeutic target in inflammatory dermatoses. J Dermatolog Treat 2008; 19: 318-26.
39. Ronnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 408-20.
40. Wenzel J, Henze S, Brahler S et al. The expression of human leukocyte antigen-DR and CD25 on circulating T cells in cutaneous lupus erythematosus and correlation with disease activity. Exp Dermatol 2005; 14: 454-9.
41. Koutouzov S, Mathian A, Dalloul A. Type-I interferons and systemic lupus erythematosus. Autoimmun Rev 2006; 5: 554-62.
42. Roers A, Hochkeppel HK, Horisberger MA et al. MxA gene expression after live virus vaccination: a sensitive marker for endogenous type I interferon. J Infect Dis 1994; 169: 807-13.
43. Horisberger MA. Interferon-induced human protein MxA is a GTPase which binds transiently to cellular proteins. J Virol 1992; 66: 4705-9.
44. Leifeld L, Ramakers J, Schneiders AM, Dumoulin FL, Sterneck M, Muller A, Sauerbruch T, Spengler U. Intrahepatic MxA expression is correlated with interferon-alpha expression in chronic and fulminant hepatitis. J Pathol 2001; 194: 478-83.
45. Jakschies D, Zachoval R, Muller R, Manns M, Nolte KU, Hochkeppel HK, Horisberger MA, Deicher H, Von Wussow P. Strong transient expression of the type I interferon-induced MxA protein in hepatitis A but not in acute hepatitis B and C. Hepatology 1994; 19: 857-65.
46. Johnson-Huang LM, McNutt NS, Krueger JG, Lowes MA. Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol 2009; 29: 247-56.
47. Lande R, Gregorio J, Facchinetti V et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007; 449: 564-9.
48. Barton GM, Kagan JC, Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol 2006; 7: 49-56.
49. Bave U, Magnusson M, Eloranta ML, Perers A, Alm GV, Ronnblom L. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol 2003; 171: 3296-302.
50. Meyers JA, Mangini AJ, Nagai T, Roff CF, Sehy D, van Seventer GA, van Seventer JM. Blockade of TLR9 agonist-induced type I interferons promotes inflammatory cytokine IFN-gamma and IL-17 secretion by activated human PBMC. Cytokine 2006; 35: 235-46.
51. Christophers E. Explaining phenotype heterogeneity in patients with psoriasis. Br J Dermatol 2008; 158: 437-41.
52. Harper EG, Guo C, Rizzo H et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 2009; 129: 2175-83.
53. Hagforsen E, Hedstrand H, Nyberg F, Michaelsson G. Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis. Br J Dermatol 2010; 163: 572-9.